Dynamics of Genome Alterations in Crohn's Disease-Associated Colorectal Carcinogenesis
Overview
Authors
Affiliations
Patients with inflammatory bowel diseases, that is, ulcerative colitis and Crohn's disease (CD), face an increased risk of developing colorectal cancer (CRC). Evidence, mainly from ulcerative colitis, suggests that mutations represent an initial step in the progression from inflamed colonic epithelium to CRC. However, the pathways involved in the evolution of CRC in patients with CD are poorly characterized. Here, we analyzed 73 tissue samples from 28 patients with CD-CRC, including precursor lesions, by targeted next-generation sequencing of 563 cancer-related genes and array-based comparative genomic hybridization. The results were compared with 24 sporadic CRCs with similar histomorphology (i.e., mucinous adenocarcinomas), and to The Cancer Genome Atlas data (TCGA). CD-CRCs showed somatic copy-number alterations (SCNAs) similar to sporadic CRCs with one notable exception: the gain of 5p was significantly more prevalent in CD-CRCs. CD-CRCs had a distinct mutation signature: (76% in CD-CRCs vs. 33% in sporadic mucinous CRCs), (24% vs. 50%), (17% vs. 75%), and (3% vs. 29%). mutations and SCNAs were early and frequent events in CD progression, while , and mutations occurred later. In four patients with CD-CRC, at least one mutation and/or SCNAs were already present in non-dysplastic colonic mucosa, indicating occult tumor evolution. Molecular profiling of CD-CRCs and precursor lesions revealed an inflammation-associated landscape of genome alterations: 5p gains and mutations occurred early in tumor development. Detection of these aberrations in precursor lesions may help predicting disease progression and distinguishes CD-associated from sporadic colorectal neoplasia. .
Machine learning‑based radiomics models accurately predict Crohn's disease‑related anorectal cancer.
Horio Y, Ikeda J, Matsumoto K, Okada S, Nagano K, Kusunoki K Oncol Lett. 2024; 28(3):421.
PMID: 39035049 PMC: 11258598. DOI: 10.3892/ol.2024.14553.
Jiang T, Zheng J, Li N, Li X, He J, Zhou J Curr Gene Ther. 2024; 24(5):422-440.
PMID: 38682449 DOI: 10.2174/0115665232294568240201073417.
Feunteun J, Ostyn P, Delaloge S iScience. 2022; 25(5):104217.
PMID: 35494254 PMC: 9044163. DOI: 10.1016/j.isci.2022.104217.
Molecular Network of Colorectal Cancer and Current Therapeutic Options.
Huang Z, Yang M Front Oncol. 2022; 12:852927.
PMID: 35463300 PMC: 9018988. DOI: 10.3389/fonc.2022.852927.
Liegmann A, Heselmeyer-Haddad K, Lischka A, Hirsch D, Chen W, Torres I Cancers (Basel). 2021; 13(13).
PMID: 34282768 PMC: 8267950. DOI: 10.3390/cancers13133366.